Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Lymphedema
Interventions: Exercise Intervention, Weight Loss Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 80 Years · Female only
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Influenza
Interventions: Peramivir, Oseltamivir; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 0 Days to 17 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 9
States / cities: Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more

Conditions: Healthy Volunteer
Interventions: DISC-0974, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma in Children
Interventions: Clinical decision support + education (CDS+) and population health management (PHM), Control; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: ENT-03, Placebo; Drug
Lead sponsor: Metabolics Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care; Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years to 98 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • Weslaco, Texas + 1 more

Conditions: Pneumococcal Vaccines
Interventions: 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Healthy
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 23 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anesthesia, Pain, Amnesia
Interventions: Sevoflurane, Peripheral Nerve Stimulation; Drug · Device
Lead sponsor: Keith M Vogt; Other
Eligibility: 18 Years to 59 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more

Conditions: Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: RGN-137, Placebo; Drug
Lead sponsor: Lenus Therapeutics, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: PTSD - Post Traumatic Stress Disorder, Depression/Anxiety
Interventions: Mobile Health Stress Self Management System, Intensive Cycling Activity; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Dental Caries, Obesity Prevention
Interventions: Hydration; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 4 Years and older
Enrollment: 7,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Henrico, Virginia

Conditions: Healthy Subjects
Interventions: INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs; Device · Other
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cincinnati, Ohio • Norfolk, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: AMG 127, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Aventura, Florida

Conditions: Alzheimer's Disease
Interventions: CPC-201; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Back Pain Lower Back Chronic, Chronic Pain, Musculoskeletal Pain
Interventions: Digital Musculoskeletal (MSK) Program, Transcutaneous Electrical Nerve Stimulation (TENS), Standard of Care (SOC); Behavioral · Device · Other
Lead sponsor: Hinge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Aging
Interventions: Gait Adaptation Training, Basic Physical Training; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Adverse Childhood Experiences, Domestic Violence
Interventions: Experimental; Behavioral
Lead sponsor: University of Nebraska Lincoln; Other
Eligibility: 10 Years and older
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rapid City, South Dakota

Conditions: Total Knee Arthroplasty, Osteoarthritis
Interventions: Physical Activity Behavior Intervention, Attention Control; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 85 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Esophageal Cancer
Interventions: capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy; Drug · Genetic · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Overweight, Obesity
Interventions: Fruit and Vegetable CSA Prescription, Bikeshare Prescription; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 24 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

The Women In Steady Exercise Research (WISER) Survivor Trial

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

SMART Implementation-Effectiveness Trial 2

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Sevoflurane's Effect on Neurocognition Study

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

An Integrative, Digital Health Approach to Veteran-Centered PTSD Care

Advancing Water Security: A Community Participatory School-Based Hydration Intervention

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Examining the Impact of a Digital Health Program and TENS Device for Patients With Chronic Low Back Pain

Gait Adaptation Study

The Impact of an Adapted Version of the Strengthening Families Program on IPV Among Caregivers and ACEs Among Children

Optimizing Physical Activity Outcomes After Total Knee Arthroplasty

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

Fruit And Vegetable Or Recreation Prescriptions for UW-Madison Students